http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11524016-B2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0f4ca46aceeb59a505c740ceee4a55a7 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d8ee528c8f30df14a305a3b802e9e5b8 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-585 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-08 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-585 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P17-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P17-14 |
| filingDate | 2020-07-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2022-12-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8af288093cc0ac27b6541da944b83f28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_92885722d7b0d1921c9123a022e1e7f3 |
| publicationDate | 2022-12-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-11524016-B2 |
| titleOfInvention | Compositions and methods for the topical administration of spironolactone for the treatment of cutaneous signs of excess androgen and chronic stress response |
| abstract | The present disclosure provides methods for treating or alleviating symptoms of a disease, disorder, or condition related to excess androgen or stress-induced skin changes in a subject in need thereof by topically administering a pharmaceutical composition comprising a pharmaceutically effective amount of spironolactone to the subject. Other aspects relate to methods for providing anti-oxidative stress, anti-inflammatory and anti-aging benefits for the skin to a subject in need thereof by topically administering a pharmaceutical composition comprising a pharmaceutically effective amount of spironolactone to the subject. Surprisingly, it has been found that spironolactone may be topically administered with reduced adverse effect compared to systemic administration of the same medication. |
| priorityDate | 2020-07-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 171.